New combo therapy aims to slow advanced breast cancer

NCT ID NCT06771609

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase II trial tests whether adding a PD-L1 antibody (adebrelimab) to a specific chemotherapy regimen (VEX) — with or without radiation — can delay cancer growth in people with advanced triple-negative breast cancer. About 150 participants will be randomly assigned to one of two treatment groups. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab (PD-L1 antibody) plus vinorelbine, cyclophosphamide, and capecitabine chemotherapy, with or without radiotherapy
What this could lead to: If successful, this could offer a new treatment option that delays cancer progression for people with advanced triple-negative breast cancer.
What could go wrong: This is an early Phase II trial with only 150 participants, so results may not apply to all patients. The combination therapy may cause significant side effects, and there is no guarantee it will improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED TRIPLE-NEGATIVE BREAST CANCER

Contacts and locations

Locations

Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.